30th Oct 2015 14:44
LONDON (Alliance News) - Silence Therapeutics PLC Friday said Quark Pharmaceuticals Inc will begin a Phase 3 trial in renal delayed graft function using its QPI-1002 drug in December.
Quark will also begin a Phase 2 trial at the same time using QPI-1002 for acute kidney injury.
Quark is owned by SBI Holdings Inc, which is a wholly-owned subsidiary of SBI Biotech Co Ltd. Silence developed the interfering Ribonucleic acid modification used in the drug.
Silence said it may receive potential milestone payments but has no future obligations in regard to the programmes.
Shares in Silence were trading up 1.6% at 172.75 pence Friday afternoon.
By Karolina Kaminska; [email protected] @KarolinaAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
SLN.L